Abstract
BRAF V600E and microsatellite instability (MSI) are two key biomarkers in metastatic colorectal cancer (mCRC). Around 30% of patients who harbor a BRAF V600E mutation are found to be MSI-high (MSI-H). Using real-world-data, this study compared overall survival (OS) by BRAF V600E status and further stratified by MSI status.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
